tbuckley/cabot-search huggingface dataset:
VHIO-300 and a thousand and one nights: A tale of precision medicine
Authors: G. Caratù, F.M. Mancuso, M. Sansó, J. Matito, R. Fasani, A. Oaknin, M. Alsina Maqueda, J. Capdevila, E. Elez Fernández, T. Macarulla Mercade, J. Carles, C. Saura, J.A. Rodon, R. Dienstmann, P.G. Nuciforo, E. Garralda, E. Felip, J. Tabernero, A. Vivancos
Journal: Annals of Oncology (2019)
Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): A pooled analisys of TRIBE and TRIBE-2 studies by GONO
Authors: E. Dell’Aquila, D. Rossini, M. Stellato, F. Bergamo, G. Aprile, F. Morano, R. Intini, E. Fea, M. Ronzoni, M. Libertini, A. Buonadonna, L. Fanchini, L. Marcucci, E. Maiello, F. Marmorino, A. Boccaccino, S. Cordio, G. Masi, A. Falcone, D. Santini
Journal: Annals of Oncology (2019)
Treatment of Bacterial Endocarditis
Authors: Maxwell Finland
Journal: New England Journal of Medicine (1954)

Oxytetracycline. Reports of therapy with oxytetracycline in 27 collected cases of bacterial endocarditis75, 113, 134, 136, 154, 164, 169–172, 174 175 176 177 178 indicate that the results were qualitatively similar to those obtained with chlortetracycline and equally difficult to evaluate (a few of these patients who were also treated with the latter antibiotic have been included among the cases treated with that agent). Although comparisons with the small numbers of cases involved are not warranted the results appear to be quantitatively slightly less favorable, for only 7 of these 29 patients achieved a favorable result and cure during the course of treatment with oxytetracycline (27 per cent recoveries from . . .
Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumours
Authors: Y.-J. Bang, M. Karayama, M. Takahashi, J. Watanabe, H. Minami, N. Yamamoto, I. Kinoshita, C.-C. Lin, Y.-H. Im, T. Fujiki, I. Achiwa, E. Kamiyama, Y. Okuda, C. Lee, S. Takahashi
Journal: Annals of Oncology (2019)
Comprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP): Retrospective molecular classification of potentially eligible patients (pts) for targeted or immunotherapy treatment (tx) using the prospective CUPISCO trial’s criteria
Authors: J.S. Ross, E.S. Sokol, H. Moch, L. Mileshkin, G. Baciarello, F. Losa, A. Beringer, M. Thomas, S. Foser, J. Elvin, N. Danziger, N. Ngo, J.Y. Tse, K. Killian, D.X. Jin, L.M. Gay, A. Krämer
Journal: Annals of Oncology (2019)
ISIS-4 - A randomised factorial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58.050 patient with suspected acute myocardial-infarction.
Authors: R Collins, R Peto, M Flather, S Parish, P Sleight, M Conway, A Pipilis, C Baigent, D Barnett, Jp Boissel, A Budaj, J Cairns, L Ceremuzynski, Af Cohen, Gui De Backer, R Diaz, F Dienstl, P Dove, Mg Franzosi, M Genoni, Da Halon, J Heikkila, C Hennekens, J Horgan, D Hunt, R Kala, N Karatzas, A Keech, M Keltai, J Kjekshus, M Kornitzer, R Koster, P Landless, P Lechleitner, A Leizorovicz, Bs Lewis, L Lundkvist, S Macmahon, A Maggioni, R Malacrida, T Meyer, T Moccetti, D Ocallaghan, E Paolasso, Ls Piegas, A Reikvam, P Ridker, T Ryan, R Schroder, R Seabragomes, Jemr Sousa, G Tognoni, A Turpie, Valentin, J Varigos, H White, L Wilhelmsen, K Woods, S Yusuf, A Piombo, La Guzman, Dc Montenegro, G Irusta, Ra Schneider, C Cuneo, Bh Chamorro, Ge Espinosa, M Moreno, Mm Rios, R Doll, K Fox, D Julian, P Meier, E Sandoya, Je Perez
Journal: The Lancet (1995)
First in human, a phase I study of ISU104, a novel ErbB3 monoclonal antibody, in patients with advanced solid tumours
Authors: S.-B. Kim, B. Keam, S. Shin, Y.S. Chae, T.M. Kim, M.-S. Kim, J.G. Kim, K. Park, J.S. Ahn, L.C. Park, E. Lee, J. Juhn, S. Kim, S.-B. Hong, M.-J. Ahn
Journal: Annals of Oncology (2019)
Clinical impact of BRAF V600E mutations in patients (pts) with resectable solitary colorectal liver metastases (CRLM)
Authors: S. Kobayashi, S. Takahashi, M. Kojima, M. Sugimoto, M. Konishi, M. Ito, T. Yoshino, N. Gotohda, H. Taniguchi
Journal: Annals of Oncology (2019)
PRODIGE67_UCGI33 ARION: Association of radiochemotherapy and immunotherapy for the treatment of unresectable oesophageal cancer: A comparative randomized phase II trial
Authors: R. Guimbaud, L. Quero, V. Vendrely, D. Tougeron, K. Benerezy, E. Samalin, T. Aparicio, L. Zitvogel, J. Selves, P. Otal, E.L. Cohen-Jonathan Moyal, J.-P. Delord, V. Pezzella, T. Filleron, A. Modesto
Journal: Annals of Oncology (2019)
Cardiac rehabilitation for heart failure can improve quality of life and fitness
Authors: Rob Cook, Peter Davidson, Rosie Martin
Journal: BMJ (2019)

The studyTaylor RS, Walker S, Ciani O, et al. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis. Health Technol Assess 2019;23:1-98.This project was funded by the NIHR Health Technology Assessment Programme (project number 15/80/30).To read the full NIHR Signal, go to https://discover.dc.nihr.ac.uk/content/signal-000803/cardiac-rehabilitation-for-heart-failure-can-improve-quality-of-life-and-fitness.
FRI-146-Long-term nucleos (t)ide-analogue treatment in chronic hepatitis B eAg (–) together with a low level of HBsAg leads to a nonexhausted HBV-specific T CD8+ response
Authors: Julia Peña Asensio, Eduardo Sanz de Villalobos, Joaquín Míquel, Antonio Madejón, Antonio Olveira Martin, Alejandro González Praetorius, Andrea Martínez de la Guerra, Francisco Javier Garcia-Samaniego Rey, Juan Ramón Larrubia
Journal: Journal of Hepatology (2019)
A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors: B. Tran, H. Kouros-Mehr, A. Fermin, L. Horvath, F. Roncolato, M. Rettig, T. Dorff, S.T. Tagawa, S.K. Subudhi, E.S. Antonarakis, A.J. Armstrong, D.P. Petrylak, K. Fizazi, M.E. Salvati, H.I. Scher
Journal: Annals of Oncology (2019)
Evaluation of the cytotoxic potencies of the major maytansinoid metabolites of antibody maytansinoid conjugates detected in vitro and in preclinical mouse models
Authors: Hans Erickson, Sharon Wilhelm, Wayne Widdison, Barbara Leece, Xiuxia Sun, Yelena Kovtun, Rajeeva Singh, Ravi Chari
Journal: Cancer Research (2008)

2150  Antibody-maytansinoid conjugates (AMCs) are anticancer agents composed of three components-a monoclonal antibody that binds specifically to a target antigen, a maytansinoid cell-killing agent (e.g., DM1 or DM4), and a linker that stably connects the two. The choice of the linker impacts both the activity and tolerability of AMCs in preclinical models. Three AMCs are currently in phase II clinical trials for the treatment of cancer -IMGN242 (huC242-DM4), IMGN901 (huN901-DM1), and trastuzumab-DM1 (T-DM1). All three conjugates consist of an average of 3-4 maytansinoid (DMx) molecules tethered to a humanized monoclonal antibody (huMab) via a stable linker. IMGN901 and IMGN242 both contain disulfide links, while T-DM1 contains a thioether link. We have isolated and identified by independent synthesis and mass spectrometry the major maytansinoid metabolites produced in COLO 205 tumor-bearing SCID mice and non-tumor bearing CD-1 mice following administration of huMab-[3H]DMx conjugates utilizing the same three linkers employed by IMGN242, IMGN901, and T-DM1. We found that the nature of the linker determines the metabolism in both target tumor tissue as well as liver tissue of mice. Surprisingly, no detectable metabolism of the macrocyclic core of the maytansinoid is observed. Instead, metabolism appears to be restricted to the linker arm of the maytansinoids. In this study, we synthesized all of the major observed metabolites and compare their cytotoxic potencies against a panel of human carcinoma cell lines to a reference maytansine standard. Two of the metabolites formed from the disulfide-linked conjugates, S-methyl-DM1 and S-methyl-DM4, were more potent than maytansine towards all cell lines tested, while the other metabolites displayed considerably less activity. The cytotoxic potencies of the different maytansinoid metabolites appear to be related to their uptake into cells.
Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Authors: S. Rutella, S.E. Church, J. Vadakekolathu, S. Reeder, A.H. Sullivan, S. Warren, J. Baughman, J. Muth, H. Park, H. Uronis, Y.-K. Kang, M.C.H. Ng, P. Enzinger, K.W. Lee, K. Huber, A. Wynter-Horton, D. Li, Y.-J. Bang, J. Davidson-Moncada, D.V. Catenacci
Journal: Annals of Oncology (2019)
Challenges in the diagnosis of paediatric pneumonia in intervention field trials: recommendations from a pneumonia field trial working group
Authors: Dina Goodman, Mary E Crocker, Farhan Pervaiz, Eric D McCollum, Kyle Steenland, Suzanne M Simkovich, Catherine H Miele, Laura L Hammitt, Phabiola Herrera, Heather J Zar, Harry Campbell, Claudio F Lanata, John P McCracken, Lisa M Thompson, Ghislaine Rosa, Miles A Kirby, Sarada Garg, Gurusamy Thangavel, Vijayalakshmi Thanasekaraan, Kalpana Balakrishnan, Carina King, Thomas Clasen, William Checkley, Abidan Nambajimana, Ajay Pillarisetti, Amit Verma, Amy Lovvorn, Anaité Diaz, Aris Papageorghiou, Ashley Toenjes, Ashlinn Quinn, Azhar Nizam, Barry Ryan, Bonnie Young, Dana Barr, Dina Goodman, Eduardo Canuz, Elisa Puzzolo, Eric McCollum, Erick Mollinedo, Fiona Majorin, Florien Ndagijimana, Ghislaine Rosa, Gurusamy Thangavel, Howard Chang, Irma Fuentes, J Jaime Miranda, JD Ntivuguruzwa, Jean Uwizeyimana, Jennifer Peel, Jeremy Sarnat, Jiawen Liao, John McCracken, Joshua Rosenthal, Juan Espinoza, JM Campbell, Kalpana Balakrishnan, Kendra Williams, Kirk Smith, Krishnendu Mukhopadhyay, Kyle Steenland, Lance Waller, Lawrence Moulton, Lindsay Jaacks, Lindsay Underhill, Lisa de la Fuentes, Lisa Elon, Lisa Thompson, Luke Naeher, Maggie Clark, Margaret Laws, Marilú Chiang, Marjorie Howard, Mary Crocker, Michael Johnson, Miles Kirby, Naveen Puttaswamy, Oscar De Leon, Phabiola Herrera, Rachel Craik, Rachel Merrick, Ricardo Piedrahita, Sankar Sambandam, Sarada Garg, Sarah Rajkumar, Savannah Gupton, Shakir Hossen, Sheela Sinharoy, Shirin Jabbarzadeh, Stella Hartinger, Steven Harvey, Suzanne Simkovich, Thomas Clasen, Usha Ramakrishnan, Vanessa Burrowes, Victor Davila-Roman, Vigneswari Aravindalochanan, William Checkley, Yunyun Chen, Zoe Sakas
Journal: The Lancet Respiratory Medicine (2019)

Pneumonia is a leading killer of children younger than 5 years despite high vaccination coverage, improved nutrition, and widespread implementation of the Integrated Management of Childhood Illnesses algorithm. Assessing the effect of interventions on childhood pneumonia is challenging because the choice of case definition and surveillance approach can affect the identification of pneumonia substantially. In anticipation of an intervention trial aimed to reduce childhood pneumonia by lowering household air pollution, we created a working group to provide recommendations regarding study design and implementation. We suggest to, first, select a standard case definition that combines acute (≤14 days) respiratory symptoms and signs and general danger signs with ancillary tests (such as chest imaging and pulse oximetry) to improve pneumonia identification; second, to prioritise active hospital-based pneumonia surveillance over passive case finding or home-based surveillance to reduce the risk of non-differential misclassification of pneumonia and, as a result, a reduced effect size in a randomised trial; and, lastly, to consider longitudinal follow-up of children younger than 1 year, as this age group has the highest incidence of severe pneumonia.
A phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT part A, B)
Authors: M. Dillon, J. Guevara, K. Mohammed, S.A. Smith, E. Dean, L. McLellan, Z. Boylan, J. Spicer, M.D. Forster, K.J. Harrington
Journal: Annals of Oncology (2019)
Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Authors: G. Prado-Vázquez, L. Trilla-Fuertes, A. Gámez-Pozo, R. López-Vacas, E. López-Camacho, A. Zapater-Moros, J.M. Arevalillo, H. Navarro, M. Díaz-Almirón, P. Maín, J Feliu Batlle, J A Fresno Vara, E.A. Espinosa
Journal: Annals of Oncology (2019)
Unprocessed Red Meat and Processed Meat Consumption: Dietary Guideline Recommendations From the Nutritional Recommendations (NutriRECS) Consortium
Authors: Bradley C. Johnston, Dena Zeraatkar, Mi Ah Han, Robin W.M. Vernooij, Claudia Valli, Regina El Dib, Catherine Marshall, Patrick J. Stover, Susan Fairweather-Taitt, Grzegorz Wójcik, Faiz Bhatia, Russell de Souza, Carlos Brotons, Joerg J. Meerpohl, Chirag J. Patel, Benjamin Djulbegovic, Pablo Alonso-Coello, Malgorzata M. Bala, Gordon H. Guyatt
Journal: Annals of Internal Medicine (2019)

This article has been corrected. The original version (PDF) is appended to this article as a Supplement. Description: Dietary guideline recommendations require consideration of the certainty in the evidence, the magnitude of potential benefits and harms, and explicit consideration of people's values and preferences. A set of recommendations on red meat and processed meat consumption was developed on the basis of 5 de novo systematic reviews that considered all of these issues. Methods: The recommendations were developed by using the Nutritional Recommendations (NutriRECS) guideline development process, which includes rigorous systematic review methodology, and GRADE methods to rate the certainty of evidence for each outcome and to move from evidence to recommendations. A panel of 14 members, including 3 community members, from 7 countries voted on the final recommendations. Strict criteria limited the conflicts of interest among panel members. Considerations of environmental impact or animal welfare did not bear on the recommendations. Four systematic reviews addressed the health effects associated with red meat and processed meat consumption, and 1 systematic review addressed people's health-related values and preferences regarding meat consumption. Recommendations: The panel suggests that adults continue current unprocessed red meat consumption (weak recommendation, low-certainty evidence). Similarly, the panel suggests adults continue current processed meat consumption (weak recommendation, low-certainty evidence). Primary Funding Source: None. (PROSPERO 2017: CRD42017074074; PROSPERO 2018: CRD42018088854)
RIBOB: A study on the efficacy and safety of ribociclib in combination with letrozole in older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior systemic therapy for advanced disease
Authors: C. Kenis, N.F. Ponde, L. Decoster, E. de Azambuja, G. Jerusalem, P. Neven, L. Dal Lago, H. Denys, P. Vuylsteke, F.P. Duhoux, H. Wildiers
Journal: Annals of Oncology (2019)
Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach
Authors: A. Mueller-Schoell, L. Klopp-Schulze, W. Huisinga, M. Joerger, P. Neven, S.L. Koolen, R.H.J. Mathijssen, S. Schmidt, C. Kloft
Journal: Annals of Oncology (2019)
CX-4945, a Selective and Orally Bioavailable Inhibitor of Protein Kinase CK2 Inhibits PI3K/Akt, JAK-STAT and NF-κB Signaling and Induces Apoptosis In Multiple Myeloma Cells
Authors: Caroline Ho, Rachel Rice, Denis Drygin, Josh Bliesath, Nicole Streiner, Adam Siddiqui-Jain, Chris Proffitt, Sean O'Brien, Kenna Anderes
Journal: Blood (2010)
Quantifying Preexisting Resistant and Persister Populations–Response
Authors: David M. McClatchy
Journal: Cancer Research (2019)

We thank Mistry and colleagues for their careful study and critique of our article (1). We are convinced that the slightly differing conclusions of the two articles are based on differences in model design and our focus on biological interpretation. Specifically, we agree that a model of only preexisting resistance does fit the data well, but results in unrealistic model parameters.The study by Mistry and colleagues (2) in which time-series data from trial cohorts are analyzed differs from our current study in that it considers only sensitive and resistant tumor cells types. In our study a third, drug-tolerant persister cell population is introduced that grows slowly in the presence of tyrosine kinase inhibitor (TKI) and can mutate into fully resistant cells, which is consistent with in vitro studies analyzing clonogenic evolution of human tumor biopsies (3, 4).Modeling the observed recurrence trajectories using only acquired resistance, we do show that this model can fit the data, but this requires unrealistically high mutation induction rates. It would be interesting to put the c variable in Mistry and colleagues' study in a biological context to assess the transition rate between sensitive and resistant compartments.Regarding the model of only preexisting resistance, the results of Mistry and colleagues' work and ours both show that this model fits the data well, but leads to very high estimates of preexisting resistance (20%–30% on average in Mistry and colleagues). This result is contradicted by clinical data, in which the vast majority of pretreatment biopsies do not contain high (or any) fractions of preexisting resistance (5, 6).In the light of these two facts, we combined both mechanisms of resistance through a carefully constrained model fit, leading to clinically reasonable and robust parameters.Note that in our model, the drug-tolerant persister compartment, while slow growing, will still proliferate while exposed to the drug and would therefore be designated as resistant if a two compartment model was forced upon our data. Consequently, our results for the combined model are in fact consistent with the preexisting model by Mistry and colleagues, as their single resistance compartment encapsulates what we distinguish as drug resistance and persistence.Mistry and colleagues state the two compartment model is necessary for model identifiability. We agree, which is why we initially used the two restricted models (only acquired or preexisting resistance). However, given the contradictions with clinical observations outlined above, we conclude that a combined model is necessary to describe clinical observations.See the original Letter to the Editor, p. 5121No potential conflicts of interest were disclosed.
Assessment of CPS+EG, neo-bioscore and modified neo-bioscore in breast cancer patients treated with preoperative systemic therapy: A multicenter cohort study
Authors: L. XU, Y. Liu, Z. Fan, Z. Jiang, Y. Liu, R. Ling, J. Zhang, Z. Yu, F. Jin, C. Wang, S. Cui, S. Wang, D. Mao, Q. Xiang, Z. Zhang, B. Zhou, Z. Liu, C. Ma, X. Duan, Y. Cui
Journal: Annals of Oncology (2019)
Therapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study
Authors: S.L. Groenland, R.A.G. Van Eerden, S.L. Koolen, D J A R Moes, I.M.E. Desar, D.J. Touw, A.L.T. Imholz, A.K.L. Reyners, H. Gelderblom, N.P. van Erp, R.H.J. Mathijssen, A.D.R. Huitema, N. Steeghs
Journal: Annals of Oncology (2019)
Development of a comprehensive next-generation targeted sequencing assay for detection of gene-fusions in solid tumors
Authors: V.K. Mittal, S.P. Myrand, D. Cyanam, P.D. Williams, G.G. Bee, A. Marcovitz, R. Gottimukkala, F. Hyland, C. Allen, E. Wong-Ho, S. Sadis, C. Van Loy, J. Kilzer, N. Khazanov
Journal: Annals of Oncology (2019)
Wedge resection with omission of lymph node dissection as an optional treatment strategy in octogenarians or older with early stage non-small cell lung cancers
Authors: T. Mimae, Y. Miyata, Y. Tsutani, K. Imai, H. Ito, H. Nakayama, N. Ikeda, M. Okada
Journal: Annals of Oncology (2019)
Pharmacological screening with Chk1 inhibitors identifies synergistic agents to overcome resistance to platinums in basal breast and ovarian cancer
Authors: A.L.A. Sanabria, C. Nieto-Jiménez, V. Corrales-Sanchez, J.C. Montero, M. Burgos, E.M. Galán-Moya, A. Pandiella, A. Ocaña
Journal: Annals of Oncology (2019)
Bowel cancer: experts advise against routine testing for everyone over 50
Authors: Elisabeth Mahase
Journal: BMJ (2019)

A panel of international experts has recommended against routine testing of everyone aged 50-79 for bowel (colorectal) cancer, advising that only those at higher risk should be considered for screening.1

The advice comes as part of a BMJ Rapid Recommendation, which looked at current guidelines and evidence. It concluded that screening should be recommended for men and women with a risk of 3% or more in the next 15 years, as this is the point at which the balance of benefits and harms tilts in favour of screening.

Most guidelines recommend screening for everyone from age 50, irrespective of their individual risk. At this age the risk of developing bowel cancer over the next 15 years is typically 1-2%, meaning that, in a group …
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm
Authors: Anna B. Halpern, Nicholas P. Howard, Megan Othus, Paul C. Hendrie, Nikita V. Baclig, Sarah A. Buckley, Mary-Elizabeth M. Percival, Pamela S. Becker, Bart L. Scott, Vivian G. Oehler, Terry B. Gernsheimer, Siobán B. Keel, Johnnie J. Orozco, Ryan D. Cassaday, Andrei R. Shustov, Garrett A. Hartley, Verna L. Welch, Elihu H. Estey, Roland B. Walter
Journal: Leukemia (2019)
Cancer care through the fire and flames: 3-year experience in the utilisation of electronic consultation and referral system at the red zone in Southern Thailand
Authors: N. Rattanakhot, A. Dechaphunkul, P. Sunpaweravong, C. Sathitruangsak, A. Maisrikrod, M. Songserm, R. Jiratrachu, D. Sangthawan, T. Peerawong, T. Phungrassami, P. Rordlamool, S. Sakdejayont
Journal: Annals of Oncology (2019)
Effects of tumor treating fields (TTFields; 150 kHz) and cisplatin or pemetrexed combination therapy on mesothelioma cells in vitro and in vivo
Authors: M. Munster, K. Gotlib, R.S. Schneiderman, Y. Porat, T. Voloshin, S. Davidi, A. Shteingauz, N. Kaynan, E. Zeevi, M. Giladi, E.D. Kirson, U. Weinberg, A. Kinzel, Y. Palti
Journal: Annals of Oncology (2019)